User profiles for Romain-David Seban
Romain SebanInstitut Curie Verified email at curie.fr Cited by 981 |
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
Purpose We aimed to evaluate if imaging biomarkers on FDG PET are associated with
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with …
18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 …
The response evaluation criteria in patients with Hodgkin lymphoma (HL) were designed for
the assessment of chemotherapy and targeted molecular agents. We investigated the …
the assessment of chemotherapy and targeted molecular agents. We investigated the …
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
Cancer-Associated Fibroblasts (CAFs) represent the most prominent component of the tumor
microenvironment (TME). Recent studies demonstrated that CAF are heterogeneous and …
microenvironment (TME). Recent studies demonstrated that CAF are heterogeneous and …
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
RD Seban, JS Nemer, A Marabelle, R Yeh… - European journal of …, 2019 - Springer
Purpose An imaging-based stratification tool is needed to identify melanoma patients who
will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying …
will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying …
Emerging and evolving concepts in cancer immunotherapy imaging
Criteria based on measurements of lesion diameter at CT have guided treatment with
historical therapies due to the strong association between tumor size and survival. Clinical …
historical therapies due to the strong association between tumor size and survival. Clinical …
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
RD Seban, A Moya-Plana, L Antonios, R Yeh… - European journal of …, 2020 - Springer
Purpose To compare the prognostic value of imaging biomarkers derived from a quantitative
analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or …
analysis of baseline 18F-FDG-PET/CT in patients with mucosal melanoma (Muc-M) or …
[HTML][HTML] Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Background Drugs targeting programmed death receptor-1 (PD-1) and its ligand PD-L1
have shown activity in multiple malignancies. Considering their novel mechanism of action, …
have shown activity in multiple malignancies. Considering their novel mechanism of action, …
Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo-or …
RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani… - Lung Cancer, 2021 - Elsevier
Objectives We aimed to compare the prognostic value of inflammatory biomarkers extracted
from pretreatment peripheral blood and [18F]-FDG PET for estimating outcomes in non-…
from pretreatment peripheral blood and [18F]-FDG PET for estimating outcomes in non-…
[HTML][HTML] Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line …
RD Seban, JB Assié, E Giroux-Leprieur, MA Massiani… - Cancers, 2020 - mdpi.com
Background: We aimed to assess the clinical utility of a previously published score combining
the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment …
the total metabolic tumor volume (TMTV) on baseline FDG-PET/CT and pretreatment …
Early 18F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab
…, B Deau-Fischer, F Peyrade, RD Seban… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab
and pembrolizumab, are associated with high response rates in patients with relapsed or …
and pembrolizumab, are associated with high response rates in patients with relapsed or …